查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014470

药物发现技术市场：2026年至2032年全球市场预测（按药物类型、检测方法、技术平台、应用和最终用户划分）

Drug Discovery Technologies Market by Drug Type, Assay Techniques, Technology Platforms, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，药物发现技术市场价值将达到 701.9 亿美元，到 2026 年将成长至 775.9 亿美元，到 2032 年将达到 1,458 亿美元，复合年增长率为 11.00%。

主要市场统计数据
基准年 2025 701.9亿美元
预计年份：2026年 775.9亿美元
预测年份 2032 1458亿美元
复合年增长率 (%) 11.00%

全面概述了重塑学术界、生物技术和製药研究环境中药物发现过程的技术的演变及其战略意义。

药物研发领域目前正经历快速的技术成熟，这正在改变各机构识别标靶、检验作用机制以及推进候选化合物研发的方式。运算能力、侦测设计和跨学科整合的进步，使得研究团队能够缩短研发週期、降低早期失败率，并获得更可靠的临床前证据。因此，学术界、生技公司和製药业的相关人员正在重新思考资源分配、伙伴关係模式和基础设施投资，以确保能够充分利用这些技术所带来的生产力提升。

计算建模、检测创新和转化基因组学的进步的融合，从根本上改变了目标选择、检验和合作模式。

药物发现领域发生了多项变革性变化，这些变化如今正在汇聚，并重新调整整个研究生态系统的优先事项。首先，计算建模和基于结构的药物设计的普及重新分配了专业知识，使小规模的团队能够利用In Silico先导化合物优化和预测药理学来攻克复杂的靶点。同时，高通量筛检平台和基于奈米技术的检测方法的广泛应用，大大增加了可用于检验早期先导化合物的实验组合数量，从而产生了更为丰富的数据集，而这些数据集需要强大的资讯学流程来处理。

到 2025 年，美国关税政策的变化对营运的影响，以及贸易措施如何重塑药物研发领域的供应链韧性和筹资策略。

到2025年，美国不断变化的关税政策的累积影响正对全球药物研发供应链和设备筹资策略产生重大的营运挑战。影响试剂、实验室耗材和某些设备类别的关税和贸易措施正在增加跨境采购的间接成本，迫使采购团队实现供应商多元化并重新评估库存策略。实际上，生产和采购高度集中的企业正面临更长的前置作业时间週期和更高的接收成本，这促使它们转向近岸外包和本地采购，以满足关键投入品的需求。

针对特定细分市场的策略性洞察揭示了药物类型、检测技术、技术平台、应用领域和最终用户目标的差异如何影响药物发现过程。

基于细分的洞察揭示了药物发现各子领域在研发路径和技术应用方面存在显着差异。从药物类型来看，生物製药倾向于优先采用能够捕捉复杂蛋白质相互作用和细胞环境的检测方法，而小分子药物则仍然偏好高通量生化和结合检测，以儘早发现先导化合物。这种差异影响着上游工程投资，生物製药计画倾向于将更多资源投入到能够评估功能结果的细胞检测和报告系统，而小分子药物计画则优先考虑基于结构的药物设计和快速高通量筛选。

美洲、欧洲、中东和非洲以及亚太地区的区域优势和政策环境如何定义基于互补能力和协作的价值链？

区域趋势是药物研发投资和能力集中方向的重要驱动因素。在美洲，成熟的创投生态系统和完善的生物製造工业基础设施为快速商业化提供了支持，研发中心通常将计算科学和高通量平台与临床开发专业知识相结合。该地区的法规结构和医保环境也影响转化研究的重点，从而促进了在研发早期阶段就产生临床可用生物标记证据的计画。

透过平台专业化、策略联盟和可扩展的服务交付，确定药物发现领域竞争地位的企业策略和伙伴关係模式。

企业级药物研发技术的发展趋势反映了专业化、策略联盟和垂直整合的整合。主要企业正日益透过结合电脑设计、客製化检测平台和检验的生物模型的专有平台来建立竞争优势。许多企业正寻求伙伴关係主导型模式，透过与专业供应商、受託研究机构(CRO) 和学术机构合作，加速能力获取，扩展处理能力和专业知识，而无需承担全部内部研发成本。

切实可行的策略措施，使高阶主管能够透过有针对性的投资，建立强大的韧性能力，降低专案风险，并加速转换成果。

希望维持产业领先地位的领导企业应采取一系列切实可行的措施，使能力建设投资与组织的风险接受度和转化研究重点保持一致。首先，应制定模组化的技术蓝图，依序投资于计算建模、高通量筛检和生理相关检测。这将确保每个新增要素都能大幅降低关键研发决策的风险。同时，应优先考虑供应链多元化和合约柔软性，以减少贸易政策和对单一供应商依赖所带来的干扰。

结合一手访谈、咨商领域专家和全面文献整合的多方法研究框架，支持稳健的策略分析。

本研究采用多种方法，结合一手访谈、专家咨询以及对同行评审文献和监管指南的系统性回顾，以确保分析的平衡性和实证性。一手研究包括与研发部门高阶领导、采购经理和技术供应商进行结构化讨论，以了解实际营运和策略重点。专家咨询则透过提供关于检测验证、药物基因体学学整合和平台互通性领域的专业观点，对这些访谈进行了补充。

整合领导者必须采取的策略挑战和营运重点，以将技术进步转化为可复製的转化成果。

总之，药物研发发生态系统正朝着整合计算科学、检测和转化研究能力的一体化模式转变，以提高早期研发的准确性和效率。这些变化正在重塑组织的优先事项，从检测方法的选择到供应链的构建，都需如此，并要求领导者采取模组化的投资策略，加强跨学科团队建设，并建立正式的伙伴关係以充分利用专业能力。贸易政策趋势和区域优势进一步增加了决策的复杂性，同时也为跨区域策略合作创造了机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 药物发现技术市场（依药物类型划分）

  • 生物製药
  • 小分子药物

第九章 依检测方法分類的药物发现技术市场

  • 结合试验
  • 生化分析
  • 基于细胞的检测
  • 报导基因分析

第十章 依技术平台分類的药物发现技术市场

  • 计算建模
  • 高通量筛检
  • 奈米科技
  • 药物基因体学
  • 结构设计

第十一章 药物发现技术市场：依应用领域划分

  • 生物标誌物生成
  • 先导化合物搜寻
  • 临床前和临床开发
  • 目标识别与检验
  • 毒性测试

第十二章 药物发现技术市场：依最终用户划分

  • 学术机构
  • 生技公司
  • 製药公司

第十三章 药物发现技术市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 药物发现技术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 药物发现技术市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国药物发现技术市场

第十七章：中国药物研发技术市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer Healthcare AG
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Covaris, LLC
  • Curia Global, Inc.
  • Elucidata Corporation
  • Eurofins Advinus Private Limited
  • Evotec SE
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare Ltd.
  • Gilead Sciences, Inc.
  • Horiba, Ltd.
  • Illumina, Inc.
  • IQVIA Inc.
  • Luminex Corporation by DiaSorin Group
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PIRAMAL PHARMA LIMITED
  • Randox Laboratories Ltd.
  • Revolution Medicines, Inc.
  • Sanofi SA
  • Sygnature Discovery Limited
  • Syngene International Limited
  • Thermo FIsher Scientific Inc.
  • VWR International LLC
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4348D129FA8B

The Drug Discovery Technologies Market was valued at USD 70.19 billion in 2025 and is projected to grow to USD 77.59 billion in 2026, with a CAGR of 11.00%, reaching USD 145.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 70.19 billion
Estimated Year [2026] USD 77.59 billion
Forecast Year [2032] USD 145.80 billion
CAGR (%) 11.00%

An integrative overview of technological evolution and strategic implications reshaping drug discovery processes across academic, biotech, and pharmaceutical research environments

The drug discovery landscape is undergoing a period of rapid technical maturation that is reshaping how organizations identify targets, validate mechanisms, and progress candidates toward development. Advances in computational capabilities, assay design, and cross-disciplinary integration are enabling research teams to compress cycles, reduce attrition in early stages, and generate higher-fidelity preclinical evidence. Consequently, stakeholders across academic, biotech, and pharmaceutical settings are re-evaluating resource allocation, partnership models, and infrastructure investments to capture the productivity gains these technologies promise.

This introduction frames the core themes addressed in the report: the convergence of wet-lab and in-silico techniques, the prioritization of translational biomarkers, and the operational implications of distributed research networks. By situating these developments within the broader R&D continuum, readers can appreciate how incremental improvements in hit identification or assay sensitivity cascade into significant changes in downstream decision gates. The ensuing sections synthesize technological trajectories, regulatory touchpoints, and commercial strategies so that leaders can make informed choices grounded in contemporary evidence rather than legacy assumptions.

How converging advances in computational modeling, assay innovation, and translational genomics are fundamentally altering target selection, validation, and collaboration models

The landscape of drug discovery has experienced several transformative shifts that are now converging to alter priorities across the research ecosystem. First, the democratization of computational modeling and structure-based design has redistributed expertise, enabling smaller teams to pursue complex targets with in-silico lead optimization and predictive pharmacology. At the same time, the proliferation of high-throughput screening platforms and nanotechnology-enhanced assay formats has multiplied the experimental permutations available for early hit validation, producing richer datasets that demand robust informatics pipelines.

Additionally, pharmacogenomics is moving from a niche precision-medicine enabler to an integral consideration in preclinical design, influencing target selection and biomarker strategies. These shifts are reinforced by an increasing emphasis on reproducibility and translational relevance, which has prompted investment in more physiologically relevant cell-based assays and reporter gene constructs that better model human biology. As a result, collaborative consortia and cross-sector partnerships are becoming the dominant operational model, combining specialized capabilities and distributing risk. Therefore, strategic planning must accommodate faster iteration cycles, multidisciplinary skill sets, and scalable data architectures to capture the full value of these transformative changes.

The operational consequences of evolving US tariff policies through 2025 and how trade measures are reshaping supply chain resilience and procurement strategies in drug discovery

The cumulative influence of US tariff policy as it has evolved into 2025 has imposed substantive operational considerations for global drug discovery supply chains and equipment procurement strategies. Tariffs and trade measures affecting reagents, laboratory consumables, and certain instrumentation categories have increased the indirect cost of cross-border sourcing, prompting procurement teams to reassess supplier diversification and inventory strategies. In practical terms, organizations with centralized manufacturing and procurement footprints have faced longer lead times and higher landed costs, incentivizing nearshoring or regional sourcing arrangements for mission-critical inputs.

Moreover, tariff-driven shifts have accentuated the strategic value of domestic manufacturing partnerships and modular procurement frameworks that can adapt to episodic trade restrictions. For research programs that rely on specialized reagents or bespoke assay kits, the ripple effects have included renegotiated supplier terms, an emphasis on validated equivalence of alternative reagents, and expanded use of contract development and manufacturing organizations with regional capabilities. Simultaneously, regulatory-compliant documentation for origin and supply chain traceability has grown in importance to avoid customs-related delays. Taken together, these dynamics have not only increased operational complexity but have also accelerated the trend toward resilient, region-aware supply chain architectures within drug discovery organizations.

Segment-driven strategic insights revealing how variations in drug type, assay techniques, technology platforms, application areas, and end-user objectives shape discovery pathways

Segmentation-driven insights reveal meaningful heterogeneity in development pathways and technology adoption across drug discovery subdomains. When viewed through the lens of drug type, Biologic Drugs tend to prioritize assays that capture complex protein interactions and cellular context, while Small-Molecule Drugs continue to favor high-throughput biochemical and binding assays for initial hit identification. This dichotomy influences upstream investments, with biologics programs often allocating greater resources to cell-based assays and reporter systems that can assess functional outcomes, whereas small-molecule efforts emphasize structure-based design and rapid screening throughput.

Assay technique segmentation underscores the interplay between binding assays, biochemical assays, cell based assays, and reporter gene assays in constructing a tiered validation strategy. Each technique serves distinct decision points: binding and biochemical assays rapidly characterize interaction and enzymatic modulation; cell based and reporter gene assays provide phenotypic relevance and pathway-level confirmation. Technology platform segmentation further clarifies capability differentials, as computational modeling and structure-based design accelerate in-silico triage, high throughput screening scales empirical testing, nanotechnology introduces novel delivery and surface-interaction modalities, and pharmacogenomics informs target prioritization through human genetic context.

Application-based segmentation-spanning biomarker discovery, lead discovery, preclinical and clinical development, target identification and validation, and toxicology testing-illustrates how different stages demand unique combinations of assays and platforms. Biomarker discovery and target validation lean on genomics-integrated approaches and physiologically relevant assays, whereas preclinical development and toxicology testing require stringent reproducibility, cross-platform concordance, and regulatory-grade documentation. Finally, end-user segmentation highlights that academic institutions, biotechnology firms, and pharmaceutical companies apply these tools for divergent objectives: academia frequently focuses on exploratory validation and novel biology, biotechnology firms prioritize translational proof-of-concept and platform differentiation, and pharmaceutical companies concentrate on risk-managed development pipelines and scalable manufacturing readiness. These segmentation insights collectively inform investment prioritization, partnership selection, and the operational sequencing of discovery activities.

How regional strengths and policy environments across the Americas, Europe Middle East & Africa, and Asia-Pacific define complementary capabilities and collaborative value chains

Regional dynamics are a powerful determinant of where and how drug discovery investments and capabilities are concentrated. In the Americas, a mature venture ecosystem and established industrial biomanufacturing base support rapid commercialization pathways, with R&D centers frequently integrating computational and high-throughput platforms alongside clinical development expertise. Regulatory frameworks and reimbursement environments in this region also influence the translational emphasis, encouraging programs that generate clinically actionable biomarker evidence early in the development cycle.

Europe, Middle East & Africa exhibits a mosaic of strengths including advanced academic research hubs, collaborative public-private consortia, and pockets of specialized biotech clusters. Cross-border collaboration and harmonized regulatory initiatives within parts of this region facilitate multicenter validation studies and comparative effectiveness research, even as geopolitical and funding variability introduce complexity for long-term program planning. Infrastructure investments and policy incentives in certain markets have catalyzed translational networks that connect discovery science with patient-centric clinical research.

Asia-Pacific demonstrates accelerating capacity across both research-intensive nations and emerging biotech markets, with significant public and private investment in high-throughput platforms, computational resources, and manufacturing scale-up. The region's emphasis on rapid iteration, cost-effective operational models, and localized supply chain development has made it a central node for both early-stage discovery activities and downstream production readiness. Consequently, cross-regional collaboration strategies often pair Americas-based clinical expertise with Asia-Pacific manufacturing agility and Europe's translational science strengths to create complementary value chains.

Corporate strategies and partnership models that determine competitive positioning through platform specialization, strategic alliances, and scalable service delivery in discovery

Company-level dynamics in drug discovery technology reflect a blend of specialization, strategic alliances, and vertical integration. Leading organizations are increasingly defining competitive advantage through proprietary platforms that combine computational design, bespoke assay panels, and validated biological models. Many firms pursue partnership-led models to accelerate capability acquisition, entering into collaborations with specialized vendors, contract research organizations, and academic centers to expand throughput and domain expertise without bearing the full cost of in-house development.

Mergers, licensing agreements, and targeted acquisitions have been used selectively to internalize high-value technologies or to secure access to unique reagent portfolios and clinical biomarker datasets. At the same time, companies are experimenting with alternative commercialization strategies, including platform-as-a-service offerings and data-access subscriptions, which realign revenue models around recurring service relationships rather than one-time sales. Intellectual property management, data governance, and regulatory positioning remain core differentiators as firms scale from exploratory programs to late-stage development. Consequently, corporate strategies increasingly emphasize interoperable technology stacks, robust validation frameworks, and commercial models that balance upfront investment with scalable service delivery.

Practical, high-impact strategic measures for executives to build resilient capabilities, de-risk pipelines, and accelerate translational outcomes through targeted investments

Industry leaders that intend to stay at the forefront should adopt a set of actionable measures that align capability investment with organizational risk appetite and translational priorities. Begin by establishing modular technology roadmaps that sequence investments in computational modeling, high-throughput screening, and physiologically relevant assays so that each addition demonstrably lowers decision risk at key development gates. Simultaneously, prioritize supply chain diversification and contractual flexibility to mitigate disruptions related to trade policy or single-source dependencies.

Invest in data infrastructure and governance frameworks that enable cross-platform integration and reproducibility, ensuring that computational outputs and experimental results can be validated and audited for regulatory submission. Pursue collaborative partnerships with academic labs and specialized vendors to access niche expertise while retaining core competencies internally. Finally, align talent strategies with these technological priorities by recruiting multidisciplinary teams that combine wet-lab experience, data science proficiency, and regulatory know-how, and provide continuous learning pathways to adapt to emergent methodologies. These actions will create a resilient operational foundation and accelerate the translation of discovery-stage insights into clinically meaningful outcomes.

A multi-method research framework blending primary interviews, domain expert consultations, and comprehensive literature synthesis to underpin robust strategic analysis

This research synthesizes a multi-method approach combining primary interviews, expert consultations, and systematic review of peer-reviewed literature and regulatory guidance to ensure a balanced and empirically grounded analysis. Primary research involved structured discussions with senior R&D leaders, procurement managers, and technology vendors to capture operational realities and strategic priorities. Expert consultations supplemented these interviews with domain-specific perspectives on assay validation, pharmacogenomic integration, and platform interoperability.

Secondary research incorporated recent literature in computational chemistry, assay development, and translational biomarker science, along with policy documents that clarify regulatory expectations for preclinical validation and supply chain traceability. Analytical methods included cross-sectional comparisons across segmentation and regional dimensions, qualitative coding of expert inputs to identify recurring themes, and scenario-based assessments to explore operational implications of trade and regulatory shifts. Throughout, methodological rigor was maintained through triangulation of sources and transparent documentation of data provenance to support confidence in the conclusions and recommendations.

Synthesis of strategic imperatives and operational priorities that leaders must adopt to translate technological advances into reproducible translational outcomes

In conclusion, the drug discovery ecosystem is transitioning toward an integrated model where computational, assay, and translational capabilities converge to increase the fidelity and efficiency of early-stage development. These changes are reshaping organizational priorities, from how assays are selected to how supply chains are structured, and they demand that leaders adopt modular investment strategies, strengthen cross-disciplinary teams, and formalize partnerships to access specialized capabilities. Trade policy dynamics and regional strengths further complicate decision-making but also present opportunities for strategic alignment across geographies.

Moving forward, success will favor organizations that combine rigorous data practices, flexible procurement strategies, and a clear linkage between technical investments and downstream clinical objectives. By adopting the actionable recommendations detailed in this report and maintaining adaptive governance practices, stakeholders can translate technological potential into reproducible, clinically relevant outcomes that withstand operational and policy headwinds.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Technologies Market, by Drug Type

  • 8.1. Biologic Drugs
  • 8.2. Small-Molecule Drugs

9. Drug Discovery Technologies Market, by Assay Techniques

  • 9.1. Binding Assays
  • 9.2. Biochemical Assays
  • 9.3. Cell Based Assays
  • 9.4. Reporter Gene Assays

10. Drug Discovery Technologies Market, by Technology Platforms

  • 10.1. Computational Modeling
  • 10.2. High Throughput Screening
  • 10.3. Nanotechnology
  • 10.4. Pharmacogenomics
  • 10.5. Structure Based Design

11. Drug Discovery Technologies Market, by Application

  • 11.1. Biomarker Discovery
  • 11.2. Lead Discovery
  • 11.3. Preclinical & Clinical Development
  • 11.4. Target Identification & Validation
  • 11.5. Toxicology Testing

12. Drug Discovery Technologies Market, by End User

  • 12.1. Academic Institutions
  • 12.2. Biotechnology Firms
  • 12.3. Pharmaceutical Companies

13. Drug Discovery Technologies Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Discovery Technologies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Technologies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug Discovery Technologies Market

17. China Drug Discovery Technologies Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories, Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer Healthcare AG
  • 18.9. Bio-Rad Laboratories, Inc.
  • 18.10. bioMerieux SA
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Covaris, LLC
  • 18.13. Curia Global, Inc.
  • 18.14. Elucidata Corporation
  • 18.15. Eurofins Advinus Private Limited
  • 18.16. Evotec SE
  • 18.17. F. Hoffmann-La Roche Ltd.
  • 18.18. GE Healthcare Ltd.
  • 18.19. Gilead Sciences, Inc.
  • 18.20. Horiba, Ltd.
  • 18.21. Illumina, Inc.
  • 18.22. IQVIA Inc.
  • 18.23. Luminex Corporation by DiaSorin Group
  • 18.24. Merck & Co., Inc.
  • 18.25. Novartis AG
  • 18.26. Pfizer Inc.
  • 18.27. PIRAMAL PHARMA LIMITED
  • 18.28. Randox Laboratories Ltd.
  • 18.29. Revolution Medicines, Inc.
  • 18.30. Sanofi S.A.
  • 18.31. Sygnature Discovery Limited
  • 18.32. Syngene International Limited
  • 18.33. Thermo FIsher Scientific Inc.
  • 18.34. VWR International LLC
  • 18.35. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 123. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. GCC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 141. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. G7 DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 147. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 148. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)